-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca Advances Ambition To Redefine Cancer Care With New Data Across Diverse Portfolio And Pipeline At ESMO Congress, October 17-21

Benzinga·10/13/2025 11:03:08
Listen to the news

Presidential Symposium will feature DESTINY-Breast11 and DESTINY-Breast05, underscoring potential of ENHERTU® (fam-trastuzumab deruxtecan-nxki) in HER2-positive early breast cancer

TROPION-Breast02 data will demonstrate potential of DATROWAY® (datopotamab deruxtecan-dlnk) in metastatic triple-negative breast cancer, most aggressive subtype

POTOMAC disease-free survival and MATTERHORN survival results will showcase benefit of IMFINZI® (durvalumab) in early bladder and gastric cancers

AstraZeneca advances its ambition to redefine cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October 17-21, 2025.

More than 95 abstracts will feature nine approved and nine potential new medicines from the Company including two abstracts featured in a late-breaking Presidential Symposium and 26 oral presentations.